Results 11 to 20 of about 779,609 (165)

CT-P13: design, development, and place in therapy [PDF]

open access: yesDrug Design, Development and Therapy, 2017
Tommaso Gabbani,1 Simona Deiana,2 Vito Annese3 1Gastroenterology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, 2Division of Gastroenterology, AOU Careggi University Hospital, Florence, Italy; 3Gastroenterology Department, Valiant ...
Gabbani T, Deiana S, Annese V
doaj   +7 more sources

Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease [PDF]

open access: yesFrontiers in Immunology
Background and aimsFavourable clinical data were published on the efficacy of CT-P13, the first biosimilar of infliximab (IFX), in pediatric inflammatory bowel disease (IBD); however, few studies have compared the effect on endoscopic healing (EH) and ...
Eun Sil Kim   +31 more
doaj   +6 more sources

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients [PDF]

open access: yesTherapeutic Advances in Gastroenterology, 2016
Many reference biological therapies have now reached or are near to patent expiry, and therefore a number of biosimilars have been or will be developed.
Jørgen Jahnsen
doaj   +4 more sources

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [PDF]

open access: yesTherapeutic Advances in Gastroenterology, 2017
Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Joana Afonso   +5 more
doaj   +6 more sources

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®). [PDF]

open access: yesDrug Des Devel Ther, 2020
To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions.This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel ...
Kim S, Kim S, Lee H.
europepmc   +10 more sources

Comparative effectiveness of the biosimilar CT-P13

open access: yesJournal of Comparative Effectiveness Research, 2017
The first biosimilar infliximab, CT-P13 (infliximab-dyyb) has been used for the treatment of inflammatory diseases for 4 years. CT-P13 has highly similar efficacy and safety profiles with a lower price than the originator infliximab and has been approved in 81 countries.
Dae Hyun Yoo
core   +4 more sources

A Review on Biosimilar Infliximab, CT-P13, in the Treatment of Inflammatory Bowel Disease [PDF]

open access: yesImmunotherapy, 2017
The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however ...
Farkas Klaudia, Molnár Tamás
openaire   +5 more sources

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study [PDF]

open access: yesBiomedicines, 2022
Background: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation.
Jose M. Huguet   +11 more
doaj   +2 more sources

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series [PDF]

open access: yesClinical Case Reports, 2022
The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased ...
Sooraj Vijayan   +2 more
doaj   +2 more sources

Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU

open access: yesClinical Drug Investigation, 2021
CT-P13 (Remsima®; Inflectra®), a biosimilar of reference infliximab (Remicade®), provides a useful alternative for patients requiring infliximab therapy and, as with other biosimilar agents, has the potential to reduce treatment costs. Furthermore, the availability of CT-P13 in a subcutaneous formulation (CT-P13 SC), with the possibility (after ...
Matt Shirley (7340599)
openaire   +3 more sources

Home - About - Disclaimer - Privacy